Higher plasma percentages of ω-3 polyunsaturated fatty acids (PUFAs) and a lower ratio of ω-6-to-ω-3 PUFAs in the late-second trimester of pregnancy are predictors of less weight retention at 18 months postpartum, according to a study involving a multiethnic Asian cohort.
Conjugated oestrogens/bazedoxifene (CE/BZA) may reduce hot flush frequency by approximately half after around 8 to 10 days of treatment, according to a posthoc analysis. Sustained improvement can be achieved with continued treatment.
Women with higher age at breast cancer diagnosis and Indian women are at a higher risk of cardiovascular disease (CVD) mortality after diagnosis, a new prospective cohort study shows. However, risk of CVD mortality within 10 years after diagnosis remains low in Southeast Asia.
Maternal depression and insensitive parenting were independently associated with infant right frontal electroencephalogram (EEG) asymmetry, which has been linked to negative emotion and behavioural difficulties, among infants who spent a substantial amount of time with their mothers, according to data from the GUSTO* longitudinal birth cohort.
Women given tranexamic acid within three hours of giving birth appear to have a reduced risk of death due to postpartum haemorrhage (PPH), according to findings of the large, multinational WOMAN* trial.
Over the past few decades, there has been widespread concern about the increasing proportion of births born by caesarean delivery. The rising rate of primary caesarean section has led to the increased number of obstetric population with a history of prior caesarean delivery. Although this group of women may be offered planned vaginal birth after previous caesarean section (VBAC) or elective repeat caesarean section (ERCS), the VBAC rate is generally low particularly in well-developed countries. In the United States, the VBAC rate has decreased to 8.5% by 2006, while the total caesarean rate has increased to 31.1%.1
Tumor necrosis factor (TNF)-α inhibitors are commonly used in the treatment of inflammatory bowel disease (IBD), but the effects of these agents on pregnancy outcomes remain unclear. Now, a systematic review of the English literature has indicated that they pose little risk to the mother or her infant, even if use is continued through the third trimester.